Skip to content

Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy

Randomized Clinical Trial of Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05199168
Enrollment
120
Registered
2022-01-20
Start date
2022-03-01
Completion date
2024-07-01
Last updated
2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

Esophageal Cancer, Minimally invasive surgery, Recurrent laryngeal nerves, Intraoperative nerve monitoring

Brief summary

The clinical value of intraoperative nerve monitoring (IONM) in thoracoscopic esophagectomy remains uncertain. The aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy.

Detailed description

Recurrent laryngeal nerves (RLN) lymph nodes are the most common metastatic areas in esophageal squamous carcinoma. It is a clinical challenge to reduce high incidence of RLN injury rate result from routine dissection of RLN lymph nodes. Thoracoscopic approach may provide a clear operative field and potentially less invasive surgery. But there are still high RLN injury rate only depending on visualization of thoracoscopy. The use of intraoperative nerve monitoring (IONM) was shown very helpful to identify the RLN and associated with a reduction of RLN injury rate in thyroidectomy. However, there is no solid clinical evidence about the effectiveness of utility of IONM in thoracoscopic esophagectomy. Thus, the aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy.

Interventions

Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Histologically proven primary intrathoracic middle and lower esophageal squamous cell carcinoma and will undergo McKeown MIE and bilateral RLN lymph ndoe dissection. 2. No superclavicular lymph node metastasis after preoperative examination. 3. No contraindication for esophagectomy. 4. Expected surgical R0 resection.

Exclusion criteria

1. Pre-existed vocal cord dysfunction. 2. Thorax pleural adhesion rendering minimal invasive approach unfeasible. 3. Gastric tube cannot be used for reconstruction. 4. Combined with hemorrhagic disease. 5. Psychiatric patients. 6. Inability to undergo curative resection and/or follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of the recurrent laryngeal nerve injuryTill 6 months postoperativelyThe vocal cord function will be assessed by an experienced otolaryngologist using a laryngoscope on 1st postoperative day.RLN palsy will be classified according to the following variables: site (unilateral versus bilateral); duration (temporary \[i.e., recovering within 6 months\] versus permanent \[i.e. not recovering within 6 months\])postoperatively.

Secondary

MeasureTime frameDescription
Number of nodes removed along the right and left RLNThe pathological analysis will be finished within 2 weeks.number of lymph node removed
Value of IONM during operation1 Day of surgery
Post esophagectomy pneumonia rateDuration of hospital stay, an expected average of 2~3 weeks.
Operation time (thoracic phase)Intraoperative

Countries

China

Contacts

Primary ContactHongjing Jiang, MD. Ph.D.
jianghongjing@tmu.edu.cn02223340123
Backup ContactZhao Ma, MD. Ph.D.
mazhao2015@163.com15620610559

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026